Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126487382 | 12648738 | 2 | F | 201601 | 20160920 | 20160812 | 20160923 | EXP | US-JNJFOC-20160808681 | JANSSEN | 70.58 | YR | E | F | Y | 52.16000 | KG | 20160923 | CN | US | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126487382 | 12648738 | 1 | SS | DOXIL | DOXORUBICIN HYDROCHLORIDE | 1 | Intravenous (not otherwise specified) | Y | N | 0 | LIPOSOME INJECTION | ||||||||
| 126487382 | 12648738 | 2 | SS | DOXIL | DOXORUBICIN HYDROCHLORIDE | 1 | Intravenous (not otherwise specified) | Y | N | 0 | LIPOSOME INJECTION | ||||||||
| 126487382 | 12648738 | 3 | SS | DOXIL | DOXORUBICIN HYDROCHLORIDE | 1 | Intravenous (not otherwise specified) | Y | N | 0 | LIPOSOME INJECTION | ||||||||
| 126487382 | 12648738 | 4 | SS | DOXIL | DOXORUBICIN HYDROCHLORIDE | 1 | Intravenous (not otherwise specified) | Y | N | 0 | LIPOSOME INJECTION | ||||||||
| 126487382 | 12648738 | 5 | SS | DOXIL | DOXORUBICIN HYDROCHLORIDE | 1 | Intravenous (not otherwise specified) | Y | N | 0 | LIPOSOME INJECTION | ||||||||
| 126487382 | 12648738 | 6 | PS | DOXIL | DOXORUBICIN HYDROCHLORIDE | 1 | Intravenous (not otherwise specified) | Y | N | 50718 | LIPOSOME INJECTION |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126487382 | 12648738 | 1 | Ovarian cancer |
| 126487382 | 12648738 | 2 | Ovarian cancer |
| 126487382 | 12648738 | 3 | Ovarian cancer |
| 126487382 | 12648738 | 4 | Ovarian cancer |
| 126487382 | 12648738 | 5 | Ovarian cancer |
| 126487382 | 12648738 | 6 | Ovarian cancer |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126487382 | 12648738 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126487382 | 12648738 | Abasia | |
| 126487382 | 12648738 | Blister | |
| 126487382 | 12648738 | Drug dose omission | |
| 126487382 | 12648738 | Hypokinesia | |
| 126487382 | 12648738 | Immobile | |
| 126487382 | 12648738 | Pain | |
| 126487382 | 12648738 | Paraesthesia | |
| 126487382 | 12648738 | Skin disorder |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 126487382 | 12648738 | 1 | 20160516 | 0 | ||
| 126487382 | 12648738 | 2 | 20160222 | 0 | ||
| 126487382 | 12648738 | 3 | 20160321 | 0 | ||
| 126487382 | 12648738 | 4 | 20160718 | 0 | ||
| 126487382 | 12648738 | 5 | 20160613 | 0 | ||
| 126487382 | 12648738 | 6 | 20151026 | 0 |